antisense in myotonic dystrophy

Isis and Biogen Idec are collaborating to develop antisense drugs for neurologic disorders; a trial of ISIS-DMPKRx for MMD1 (DM1) is expected in 2014

posted on September 10, 2013 - 4:55pm
Update (Oct. 16, 2013): Isis announced in an Oct.

New content is being added every day. Please check back again.